PMC

Effect of Biobran and/or X-ray irradiation on body weight change (g). Each value represents the mean ± SE of 8–11 mice. Number of mice/group for (Initial, Net Final BW): Normal Control (8, 8), Normal Biobran (8, 8), Inocul Control (11, 10), Inocul Biobran (11, 11), Inocul Rad (11, 6), Inocul Biobran + Rad (11, 10). ^a,ASignificantly different from the net final BW of Normal Control group at P < 0.05, P < 0.01 levels. ^BSignificantly different from the net final BW of Normal Biobran group at P < 0.01 level. ^CSignificantly different from the net final BW of Inocul Control group at P < 0.01 level. ^DSignificantly different from the net final BW of Inocul Biobran group at P < 0.01 level. ^ESignificantly different from the net final BW of Inocul Rad group at P < 0.01 level.

(A) Effect of Biobran and/or Rad on tumor weight. Each value represents the mean ± SE. Number of mice/group; Inocul Control (10), Inocul Biobran (11), Inocul Rad (6), Inocul Biobran + Rad (10). (B) Representative photograph of tumor regression after treatment with Biobran and/or X-ray irradiation after 30 days. ^ASignificantly different from Inocul Control group at P ≤ 0.01 level. ^b,BSignificantly different from Inocul Biobran group at P ≤ 0.05, P ≤ 0.01 levels, respectively. ^CSignificantly different from Inocul Rad group at P ≤ 0.01 level.

Percentage of animals showing dysplasia or adenocarcinoma after treatment with both MNNG and Biobran. Animals were treated under different conditions: control untreated, Biobran alone, MNNG alone, and MNNG plus Biobran. The percentages of dysplasia and adenocarcinoma were examined at 8 months posttreatment. No dysplasia or adenocarcinoma were detected in the control untreated or Biobran alone treated rats. Each group contains 7 to 12 rats. *P < .01 compared to MNNG plus Biobran.

The levels of IFN-γ among patients on Biobran before and three months after treatment (n = 16).